Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AD-MSCs in moderate to severe psoriasis
NCT03265613Phase 2Completed
- Sponsor
- Guangdong Provincial Hospital of Traditional Chinese Medicine
- Start
- Sep 2017
- Primary completion
- Aug 2019
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adipose derived mesenchymal stromal cells in Psoriasis vulgaris (PV), sponsored by Guangdong Provincial Hospital of Traditional Chinese Medicine. Primary endpoints: Adverse Events at 12 weeks and Serious Adverse Events at 12 weeks. Started Sep 2017; status: completed.
02
Drugs
adipose derived mesenchymal stromal cells
03
Conditions
Psoriasis vulgaris (PV)
Beyond the preview
Go deeper on NCT03265613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03265613.